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Abstract 
Summary:  Polymerase chain reaction-based assays are the current gold standard for detecting and 
diagnosing SARS-CoV-2.  However, as SARS-CoV-2 mutates, we need to constantly assess whether 
existing PCR-based assays will continue to detect all known viral strains.  To enable the continuous 
monitoring of SARS-CoV-2 assays, we have developed a web-based assay validation algorithm that 
checks existing PCR-based assays against the ever-expanding genome databases for SARS-CoV-2 
using both thermodynamic and edit-distance metrics. The assay screening results are displayed as a 
heatmap, showing the number of mismatches between each detection and each SARS-CoV-2 genome 
sequence.  Using a mismatch threshold to define detection failure, assay performance is summarized 
with the true positive rate (recall) to simplify assay comparisons.  
Availability:  https://covid19.edgebioinformatics.org/#/assayValidation  
Contact: Jason Gans (jgans@lanl.gov) and Patrick Chain (pchain@lanl.gov)  
1 Introduction  
Many aspects of the control, management and treatment responses to the 
global COVID-19 pandemic require accurate detection of its causative 
agent, SARS-CoV-2. To address this challenge, research groups around 
the world have developed Polymerase Chain Reaction (PCR)-based 
assays to detect SARS-CoV-2 genomic RNA (Supplementary Tables S1). 
 The impact of SARS-CoV-2 genetic drift on the ability of PCR-based 
assays to successfully detect target sequences is a concern. To address this 
concern, we have developed a web-based application that monitors 
existing SARS-CoV-2 PCR-based assays that are in use around the world 
and provides a visual summary of assay performance.  Both the acquisition 
of new genomes and the assay validation process is automated, so that 
assays are checked and displayed daily to give near real-time results.  
2 Implementation 
 The core of the validation algorithm is the ThermonucleotideBLAST 
(Gans and Wolinsky, 2008) in silico PCR screening tool. Publicly 
available assays are used as queries in ThermonucleotideBLAST and 
searched against a target database of SARS-CoV-2 genomes from the 
Global Initiative on Sharing All Influenza Data (GISAID) (Shu and 
McCauley, 2017) and Genbank (Clark et al., 2016).   
Sequences are downloaded daily from these databases and filtered to 
exclude any that are less than 29 kilobases or are pangolin-SARS and bat-
SARS. For sequences found in both databases, only the GenBank version 
is retained. True positives are defined as any assay-target pairwise 
alignment that contains in 0, 1, or 2 mismatches (in the oligonucleotide 
with the most mismatches).  False negatives are defined as an assay/target 
combination that has either (a) one or more oligo/target pairwise 
alignments with 3 or more mismatches, or (b) one or more predicted 
oligo/target melting temperatures less than 40°C. Since all of the included 
assays are intended to detect SARS-CoV-2 and false positives are not 
predicted, assay performance is quantified by the recall (defined as the 
number of true positives divided by the sum of true positives and false 
negatives). 
  
Figure 1. Visualization of in silico evaluation of diagnostic assays. (A) Dashboard 
including a bar chart and table with per-assay recall and mismatch counts; (B) Phylogenetic 
tree created from high-quality genomes color-labeled by continent; (C) A heatmap display 
of assay assessment per assay per genome; (D) Assay details and statistics of genomes with 
mismatches; (E) Detailed assay evaluation results, including alignments and 
thermodynamic information. 
Per-assay recall values are summarized in the dashboard (Fig. 1A). The 
assays with the best recall rates are shown in a bar chart, which also 
displays detailed mismatch counts. The total mismatch and failure results 
are summarized in the per-assay table of aggregated data. Selecting any 
bar in the chart or assay in the table will display additional information on 
the distribution of targets with mismatches (Fig. 1D). 
A phylogenetic tree (Fig. 1B), created using PhaME (Shakya et al. 
2020), is derived from genomes defined by GISAID as high-quality (<1% 
Ns and <0.05% unique mutations). The leaves on the tree are represented 
by the genome labels and color-coded by geographic location. Mousing 
over the genome labels displays metadata associated with the sample. 
Identical SARS-CoV-2 sequences are clustered and represented as 
collapsed branches in the tree. The heatmap (Fig. 1C), color-coded to 
indicate the number of mismatches, shows analysis of every combination 
of assay and SARS-CoV-2 genome sequence. Selecting an individual cell 
of the heatmap displays detailed pairwise alignment information (Fig. 1E). 
This visualization is rendered using a custom PhyD3 phylogenetic tree 
viewer (Kreft et al., 2017). 
3   Discussion 
Few other public resources exist for assessing the performance of PCR-
based SARS-CoV-2 assays. GISAID, one of the primary repositories for 
SARS-CoV-2 genomes, provides a high-level summary of PCR-based 
assay performance for registered users. However, this information is 
provided in the form of a static image with only a limited amount of 
information. The virological.org website provides static tables 
summarizing the high-level performance of PCR assays that have been 
periodically uploaded (Holland et al., 2020). Unlike these resources, the 
web-based application presented here provides a more detailed and 
interactive view of molecular assay performance that is updated regularly 
with recently deposited genomes (>31K as of May 22, 2020). 
The heatmap-phylogeny view reveals patterns in predicted assay 
performance, including mismatches for the Charité RdRP assays (Vogels 
et al., 2020, Corman, et al., 2020) that were originally developed for 
testing SARS and/or SARS-related bat coronaviruses (Fig. 1C). A 
different pattern, previously noted by Vogels et al. (Vogels et al., 2020), 
is seen within a subset of phylogenetically related strains due to a 
mismatch in the USA CDC N3 assay (CDC, 2020). Finally, a set of 
regularly updated assay designs are also included. Each of these assays is 
selected to individually maximize the predicted recall while maintaining 
multiplex compatibility with the other assays in the set. As genomics 
continues to be used for understanding pathogen outbreaks, resources such 
as the one provided by this website may help in the early identification of 
potential assay concerns, and provide guidance on alternate assay designs 
early on, to mitigate current assays that may be eroding.  
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Supplem
entary Table S1: Publicly available assays and the sequences of the assay oligonucleotides 
N
am
e 
5-Forw
ard-3’ 
5’-R
everse-3’ 
5’-Probe-3’ 
Source (See 
https://w
w
w
.w
ho.int/em
ergencies/diseases/novel-
coronavirus-2019/technical-guidance/laboratory-
guidance) 
C
D
C
-2019-nC
oV_N
1 
GACCCCAAAATCAGCGAAAT 
TCTGGTTACTGCCAGTTGAATCTG 
ACCCCGCATTACGTTTGGTGGACC 
https://w
w
w
.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-
panel-prim
er-probes.htm
l 
C
D
C
-2019-nC
oV_N
2 
TTACAAACATTGGCCGCAAA 
GCGCGACATTCCGAAGAA 
ACAATTTGCCCCCAGCGCTTC 
https://w
w
w
.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-
panel-prim
er-probes.htm
l 
C
D
C
-2019-nC
oV_N
3 
GGGAGCCTTGAATACACCAAAA 
TGTAGCACGATTGCAGCATTG 
AYCACATTGGCACCCGCAATCCTG 
https://w
w
w
.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-
panel-prim
er-probes.htm
l 
C
hina-C
D
C
-O
R
F1ab 
CCCTGTGGGTTTTACACTTAA 
ACGATTGTGCATCAGCTGA 
CCGTCTGCGGTATGTGGAAAGGTTATGG https://w
w
w
.nejm
.org/doi/10.1056/N
EJM
oa2001017 
C
hina-C
D
C
-N
 
GGGGAACTTCTCCTGCTAGAAT 
CAGACATTTTGCTCTCAAGCTG 
TTGCTGCTGCTTGACAGATT 
https://w
w
w
.nejm
.org/doi/10.1056/N
EJM
oa2001017 
C
harite-R
dR
P_P1 
GTGARATGGTCATGTGTGGCGG 
CARATGTTAAASACACTATTAGCATA CCAGGTGGWACRTCATCMGGTGATGC 
https://w
w
w
.w
ho.int/docs/default-
source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2 
C
harite-R
dR
P_P2 
GTGARATGGTCATGTGTGGCGG 
CARATGTTAAASACACTATTAGCATA CAGGTGGAACCTCATCAGGAGATGC 
https://w
w
w
.w
ho.int/docs/default-
source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2 
C
harite-E_Sarbeco 
ACAGGTACGTTAATAGTTAATAGCGT ATATTGCAGCAGTACGCACACA 
ACACTAGCCATCCTTACTGCGCTTCG 
https://w
w
w
.w
ho.int/docs/default-
source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2 
H
KU
-O
R
F1b-nsp 
TGGGGYTTTACRGGTAACCT 
AACRCGCTTAACAAAGCACTC 
TAGTTGTGATGCWATCATGACTAG 
https://w
w
w
.w
ho.int/docs/default-
source/coronaviruse/peiris-protocol-16-1-
20.pdf?sfvrsn=af1aac73_4 
H
KU
-N
 
TAATCAGACAAGGAACTGATTA 
CGAAGGTGTGACTTCCATG 
GCAAATTGTGCAATTTGCGG 
https://w
w
w
.w
ho.int/docs/default-
source/coronaviruse/peiris-protocol-16-1-
20.pdf?sfvrsn=af1aac73_4 
W
H
-N
IC
-N
 
CGTTTGGTGGACCCTCAGAT 
CCCCACTGCGTTCTCCATT 
CAACTGGCAGTAACCA 
https://w
w
w
.w
ho.int/docs/default-
source/coronaviruse/conventional-rt-pcr-follow
ed-by-
sequencing-for-detection-of-ncov-rirl-nat-inst-health-
t.pdf?sfvrsn=42271c6d_4 
N
IID
_2019-nC
O
V_N
 
AAATTTTGGGGACCAGGAAC 
TGGCACCTGTGTAGGTCAAC 
ATGTCGCGCATTGGCATGGA 
https://w
w
w
.jstage.jst.go.jp/article/yoken/advpub/0/advpub
_JJID
.2020.061/_pdf 
nC
oV_IP2 
ATGAGCTTAGTCCTGTTG 
CTCCCTTTGTTGTGTTGT 
AGATGTCTTGTGCTGCCGGTA 
https://w
w
w
.w
ho.int/docs/default-source/coronaviruse/real-
tim
e-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-
pasteur-paris.pdf?sfvrsn=3662fcb6_2 
nC
oV_IP4 
GGTAACTGGTATGATTTCG 
CTGGTCAAGGTTAATATAGG 
TCATACAAACCACGCCAGG 
https://w
w
w
.w
ho.int/docs/default-source/coronaviruse/real-
tim
e-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-
pasteur-paris.pdf?sfvrsn=3662fcb6_2 
   
Discussion Addendum
 
W
hile there are m
any sources of em
pirical assay validation, only 
a few
 current resources exist that present predictive assessm
ents.  
O
nline repositories and m
essage groups now
 offer the m
eans for 
presenting and sharing inform
ation related to the perform
ance of 
current assays.  This inform
ation can take the form
 of static 
analyses (W
hich presum
ably em
ploy in silico predictive m
odels 
for perform
ance assessm
ent) or sim
ply sharing of inform
ation 
(often in m
anuscript form
at) in a w
orkspace or topic group chat. 
G
ISA
ID
 (Shu, et al., 2017), in addition to being a repository for 
SA
R
-C
oV
-2 genom
es, supplies bioinform
atic analyses of the 
database and a sum
m
ary of assay perform
ance.  The assay 
assessm
ent form
at is a static slide w
ith sum
m
ary inform
ation.  The 
nature of the content supplied here has varied over tim
e.  Early, the 
slide show
ed selected assays and listed genom
es w
ith m
ism
atches 
to the assay (also indicating the specific m
ism
atches).  A
s the 
num
ber of genom
es has grow
n, the list of genom
es on this slide 
grew
, w
hile losing the specific m
ism
atch inform
ation.  This w
as 
subsequently replaced w
ith a list of assays and their m
ism
atches 
w
ith respect to a reference genom
e.  The current display show
s a 
histogram
 of the percent of genom
es w
ith a m
utation in the prim
er 
region for each assay and another histogram
 w
ith the percent of 
genom
es w
ith a m
utation in the five 3’ term
inal nucleotides.  This 
analysis is developed from
 B
LA
STN
 searches.  In general, 
G
ISA
ID
 offers useful analysis, but the content has varied over tim
e 
and the presentation is static.  U
pdates to the analysis are frequent 
but unpredictable. 
In contrast, virological.org provides a forum
 for discussion of 
virus bioinform
atics analysis.  Inform
ation m
ay be presented in a 
static 
form
at, 
such 
as 
a 
m
anuscript. 
 
W
hile 
this 
enables 
conversation on the topic, the analysis is static, and inform
ation is 
only updated as often as posters choose to upload to the site. 
O
ur w
eb-based application provides an alternative that is 
interactive and updated daily w
ith recently deposited genom
es.  
O
ur analysis uses an in silico algorithm
 that is predictive of assay 
perform
ance.  A
 glance at the heatm
ap w
ill quickly reveal patterns 
and trends in the perform
ance of the assays.   
It is im
m
ediately evident that tw
o of the C
harité assays for R
dR
P 
are im
perfect m
atches to all strains of SA
R
S-C
oV
-2 (Fig. S1).  
Figures S2 and S3 show
 the alignm
ents of the probe 1 and probe 2 
assay (respectively) to Turkey/6224-A
nkara1034 genom
e as an 
exam
ple.  It is evident that both assays have one consistent 
m
ism
atch in the reverse prim
er and the P1 assay has tw
o 
m
ism
atches in the probe.  These m
ism
atches occur on all genom
es 
visualized. The alignm
ent show
s that the C
harité reverse prim
er 
has a G
 or a C
 opposite a T in the genom
e.  Evidently, the C
harité 
assay has been designed w
ith a degenerate base at this position 
w
here the SA
R
S-C
oV
-2 genom
e appears to consistently have a T.  
This design appears to be a relic of the fact that this prim
er w
as 
initially designed for testing for SA
R
S or bat-SA
R
S coronaviruses 
(V
ogels et al., 2020). 
A
nother pattern that is evident from
 the heatm
ap (Fig. S1) is that 
the N
3 assay from
 U
SA
 C
D
C
 has a num
ber of strains w
ith a single 
m
ism
atch as w
ell.  This is a T base in the forw
ard prim
er that 
m
ism
atches w
ith a G
 on the target genom
e (V
ogels et al., 2020) 
(Fig S4).  W
hile m
ost strains of virus do not have this m
ism
atch 
w
ith the assay at this base, a certain num
ber of strains appear to 
have acquired this m
utation.  The tree reveals that there is a clade 
w
ith 25 strains that have acquired this m
utation resulting in the 
m
ism
atch to the N
3 assay (Fig. S5).  M
ost of these strains originate 
from
 A
sia and O
ceania, w
ith a few
 in N
orth A
m
erican and Europe.  
The m
ajority of these strains w
ere collected in early M
arch, 
corroborating a com
m
on origin for this clade.  The rem
ainder of 
strains w
ith this m
utation do not appear to share an obviously 
delineated clade (Fig. S6), but m
any of these originate from
 A
sia 
and O
ceania and m
any have a collection date of late February and 
early M
arch (w
ith som
e as early as January) suggesting an earlier 
origin for the m
utation in this group. 
O
ther sm
all clusters of m
utations abound.  There is a sm
all clade 
of 23 sequences that cause failure of the N
1 assay due to 3 
m
ism
atches on the probe (Fig. S7).  These bases (A
C
C
)  are on the 
first three bases of the probe opposite TG
A
 (Fig. S8).  W
hile C-A
 
is a literal m
ism
atch, the rem
aining tw
o bases should not pair due 
to the therm
odynam
ic unfavorability of their position on the end 
of an oligo.  The m
ajority of these sequences originate in O
ceania 
in early M
arch.  There does not appear to be nearby clades w
ith 
m
ism
atches, so this group appears to have em
erged fairly rapidly.  
This is the type of developm
ent that w
ill potentially lead to 
obsolescence of assays, and so the ability to track these types of 
events is particularly valuable. 
H
ere w
e have presented a w
eb-based tool for visual and 
quantitative predictive assessm
ent and validation of PC
R
 assays 
that are designed to detect SA
R
S-C
oV
-2.  The tool w
e have 
described provides an easy-to-read visual representation of assay 
perform
ance 
w
ith 
respect 
to 
the 
target 
genom
es 
and 
the 
evolutionary 
relationship 
betw
een 
the 
genom
es. 
 
This 
w
eb 
application w
ill thus offer utility to policy m
akers, health officials, 
and other stakeholders in m
aking decisions about C
O
V
ID
-19 
testing and tracking of the SA
R
S-C
oV
-2 virus.
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